<abstract xmlns="http://www.w3.org/1999/xhtml">

<p>The study aimed to investigate the triglycerides to HDL-cholesterol ratio (Tg/HDL) and the interaction of this ratio with insulin resistance (IR) and insulin secretion indices, with the levels of interleukin - 1(IL-1), interleukin-6 (Il-6), and tumour necrotic factor-α (TNF-α) in sera among patients with metabolic syndrome (MS). A prospective, cross-sectional, comparative study was conducted on 45 patients with MS without data for hyperglycemia and 21 metabolically healthy non-obese controls. The levels of fasting and postprandial glucose, immunoreactive insulin (IRI), total cholesterol, triglycerides (Tg), IL-1, IL-6, and TNF-α were measured in all the participants. We calculated the LDL cholesterol levels, Tg/HDL ratio, homeostatic model of insulin resistance (HOMA-IR), and the homeostatic model of β-cell function (HOMA-b). Patients with MS had higher BMI (38.73±1.84 vs. 24.32±2.71 kg/m2; р&lt;0.05) and waist circumference (115.56 ±4.7 vs. 81.1±8.4cm; р&lt;0.05) than non-obese controls. The same patients had higher LDL cholesterol levels (3.42±0.3 vs. 2.63±0.66 mmol/l; р&lt;0.05) and Tg (1.59±0.22 vs. 1.08±0.31mmol/l; р&lt;0.05), as well as lower levels of HDL-cholesterol (1.03±0.09 vs. 1.27 ± 0.24mmol/l; р&lt;0.05) compared to the controls. The Tg/HDL ratio was 2.03±0.87 among the patients with MS and 0.88±0.27 in controls; р&lt;0.05. The plasma levels of basal IRI (19.32±3.22 mIU/l vs. 9.13±0.73mIU/l; р&lt;0.05), HOMA-IR (4.02 vs. 1.97; р&lt;0.05) and HOMA-b (258.77±57.76 vs. 183.31±17.52; р&lt;0.05) were significantly higher in the MS group. The same patients with MS had higher concentrations of IL-1 (18.37±4.28pg/ml vs. 7.12±1.74pg/ml; p&lt;0.05), IL-6 (1.01±0.3pg/ml vs. 0.1±0.3pg/ml; р&lt;0.05) and TNF-α (2.13±1.43 pg/ml vs. 1.82±0.94pg/ml; р=0.24) too. Positive correlations between the levels of IL-1 and Tg/HDL ratio (r= 0.46; p=0.008), IL-1 and HOMA-%В (r=0.47; p=0.005) were found. The Tg/HDL ratio is a potential, cheap and available surrogate marker for screening for cardiovascular risk and insulin resistance in patients with MS in clinical practice.</p>
</abstract>

The study aimed to investigate the triglycerides to HDL-cholesterol ratio (Tg/HDL) and the interaction of this ratio with insulin resistance (IR) and insulin secretion indices, with the levels of interleukin - 1(IL-1), interleukin-6 (Il-6), and tumour necrotic factor-α (TNF-α) in sera among patients with metabolic syndrome (MS). A prospective, cross-sectional, comparative study was conducted on 45 patients with MS without data for hyperglycemia and 21 metabolically healthy non-obese controls. The levels of fasting and postprandial glucose, immunoreactive insulin (IRI), total cholesterol, triglycerides (Tg), IL-1, IL-6, and TNF-α were measured in all the participants. We calculated the LDL cholesterol levels, Tg/HDL ratio, homeostatic model of insulin resistance (HOMA-IR), and the homeostatic model of β-cell function (HOMA-b). Patients with MS had higher BMI (38.73±1.84 vs. 24.32±2.71 kg/m2; р<0.05) and waist circumference (115.56 ±4.7 vs. 81.1±8.4cm; р<0.05) than non-obese controls. The same patients had higher LDL cholesterol levels (3.42±0.3 vs. 2.63±0.66 mmol/l; р<0.05) and Tg (1.59±0.22 vs. 1.08±0.31mmol/l; р<0.05), as well as lower levels of HDL-cholesterol (1.03±0.09 vs. 1.27 ± 0.24mmol/l; р<0.05) compared to the controls. The Tg/HDL ratio was 2.03±0.87 among the patients with MS and 0.88±0.27 in controls; р<0.05. The plasma levels of basal IRI (19.32±3.22 mIU/l vs. 9.13±0.73mIU/l; р<0.05), HOMA-IR (4.02 vs. 1.97; р<0.05) and HOMA-b (258.77±57.76 vs. 183.31±17.52; р<0.05) were significantly higher in the MS group. The same patients with MS had higher concentrations of IL-1 (18.37±4.28pg/ml vs. 7.12±1.74pg/ml; p<0.05), IL-6 (1.01±0.3pg/ml vs. 0.1±0.3pg/ml; р<0.05) and TNF-α (2.13±1.43 pg/ml vs. 1.82±0.94pg/ml; р=0.24) too. Positive correlations between the levels of IL-1 and Tg/HDL ratio (r= 0.46; p=0.008), IL-1 and HOMA-%В (r=0.47; p=0.005) were found. The Tg/HDL ratio is a potential, cheap and available surrogate marker for screening for cardiovascular risk and insulin resistance in patients with MS in clinical practice.

The Role of Triglyceride to HDL Cholesterol Ratio in Sera as a Clinical Surrogate Marker for Cardiovascular Risk and Insulin Resistance in Patients with Metabolic Syndrome

Dr. Georgi Stranski University Hospital - Pleven

Medico-Diagnostic Laboratory of Immunology

Journal of Biomedical and Clinical Research

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

The study aimed to investigate the triglycerides to HDL-cholesterol ratio (Tg/HDL) and the interaction of this ratio with insulin resistance (IR) and insulin...

The Role of Triglyceride to HDL Cholesterol Ratio in Sera as a Clinical Surrogate Marker for Cardiovascular Risk and Insulin Resistance in Patients with Metabolic Syndrome

Data publikacji: 18 sty 2022

Zakres stron: 162 - 168

Otrzymano: 28 sty 2021

Przyjęty: 08 lip 2021

DOI: https://doi.org/10.2478/jbcr-2021-0012

Słowa kluczowe
metabolic syndrome, insulin resistance, atherogenic index, cytokines

© 2021 Silviya S. Ganeva et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

The Role of Triglyceride to HDL Cholesterol Ratio in Sera as a Clinical Surrogate Marker for Cardiovascular Risk and Insulin Resistance in Patients with Metabolic Syndrome

Data publikacji: 18 sty 2022

Zakres stron: 162 - 168

Otrzymano: 28 sty 2021

Przyjęty: 08 lip 2021

DOI: https://doi.org/10.2478/jbcr-2021-0012

Słowa kluczowemetabolic syndrome, insulin resistance, atherogenic index, cytokines

© 2021 Silviya S. Ganeva et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Słowa kluczowe
metabolic syndrome, insulin resistance, atherogenic index, cytokines